# OnCo record paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020" ;
  schema:name "REMORA: lenvatinib in advanced or metastatic thymic carcinoma"@en ;
  schema:description "In a Japanese trial the multi-kinase inhibitor lenvatinib shrank thymic carcinoma in about four in ten patients whose disease had progressed after platinum chemotherapy, leading to its approval in Japan."@en ;
  schema:url <https://onco.cc/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30162-5>, <https://pubmed.ncbi.nlm.nih.gov/32502444/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30162-5> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Sato J, Satouchi M, Itoh S, et al." ;
  onco:cancers <https://onco.cc/cancers/thymic-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .